RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Japan’s Terumo, a medical device company, has agreed to pay $130 million to acquire Essen Technology (Beijing), which makes drug eluting stents. Terumo will also be responsible for a milestone payment, if sales goals are met. Terumo already sells interventional medical products in China, but the company does not market its own stents there. Essen reported revenues of $20 million per year.
Source: China Biotoday
